Loading
Since 2023 manufacturers must rebate Medicare when a drug's price rises faster than inflation; applying the same rule to commercial plans would end the yearly list-price rises that drive coinsurance up.
The Inflation Reduction Act of 2022 requires manufacturers to pay rebates on Part B and Part D drugs whose prices rise faster than the consumer price index. Commercial plans have no such protection, and oncology drugs have historically had annual list-price increases well above inflation. Extending the rebate to the commercial market, or letting employers piggyback on the Medicare calculation, would cap post-launch price growth across the whole system.
Shares Financial toxicity, Prices and value.
Shares Oncology drug pricing and price transparency, Prices and value.
Shares Financial toxicity, Prices and value.
Shares Oncology drug pricing and price transparency, Financial toxicity, Prices and value.
Shares Financial toxicity, Prices and value.
Shares Financial toxicity, Prices and value.
Shares Oncology drug pricing and price transparency, Financial toxicity, Prices and value.
Shares Oncology drug pricing and price transparency, Financial toxicity, Prices and value.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/